Clinical Outcome of Liver Transplant Patients With Tacrolimus-based Immunosuppression

Plain-language summary

This observational study examines the clinical outcomes of patients who received Tacrolimus-based immunosuppression after liver transplant. Patients aged 20 to 65 who had a living-donor liver transplant between 2008 and 2017 and had consented to genetic study in earlier research were included. This was a phase-not-applicable study and has been completed.

The summary above is a plain-language rendering of the official record. The original English title is shown for reference.

Trial details

Phase

N/A

Status

Completed

Sponsor

National Taiwan University Hospital

Start date

6/6/2019

Estimated completion

9/22/2020

Countries

Taiwan

Related genes

Locations

• Taipei, Taiwan

Eligibility criteria

Criteria are reproduced from the ClinicalTrials.gov record in the original English. Only the trial team can determine eligibility.

Eligible patients were those who had signed informed consent for genetic study in our previous research projects.

Inclusion Criteria of the Previous Study:

* patients who underwent living-donor liver transplantation during January 2008 to December 2017
* at the age of 20-65
* with tacrolimus-based immunosuppression after liver transplant for at least 6 months.

Exclusion Criteria of the Previous Study :

* retransplantation
* multi-organ transplantation
* human immunodeficiency virus (HIV) positive.